

July 02, 2024

The Secretary, Listing Department, National Stock Exchange of India Limited Exchange Plaza, 5th Floor, C/1 G Block, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 (Scrip Code: THYROCARE)

The Secretary, Listing Department, **BSE** Limited Phiroze Jeejeeboy Towers Dalal Street, Mumbai- 400 001 (Scrip Code: 539871)

Dear Sir/Madam,

Subject: Intimation regarding execution of Business Transfer Agreement ("BTA") with **Polo Labs Private Limited.**

Dear Sir/Madam,

This is to inform you that the Company has entered into Business Transfer Agreement ("BTA") on July 02, 2024, around 7.30 pm with, inter-alia, Polo Labs Private Limited ("Polo") and existing shareholders of Polo, by which our Company would be acquiring Polo's diagnostic and pathological services business (including without limitation, the equipment(s), assets, intellectual property rights, brands, clients, franchise business), as a going concern (on a slump sale basis). The said acquisition is subject to fulfilment of the Conditions Precedent and the Closing shall take place within [30 (Thirty) Business Days] from the date of receipt of the CP Completion Certificate to the satisfaction of the Company, subject to a Long Stop of 60 Business Days from the Execution Date of the BTA.

Details required under Regulation 30 of the Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is appended as the Annexure - 1 to this Letter.

Yours Faithfully. For Thyrocare Technologies Limited

Ramjee Dorai Company Secretary and Compliance officer

Encl: A/a



Annexure 1

Disclosure of information pursuant to Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

C.	Dortionlars	Digalogues
Sr	Particulars	Disclosures
1	Name of the target entity, details in brief	Not applicable as no entity is being
	such as size, turnover, etc;	acquired, as such.
		Datails of the transaction.
		Details of the transaction:
		The proposed transaction envisages our Company's (TTL's) acquisition and
		purchase of the Business undertaking
		pertaining to diagnostics and pathological
		services business carried out by Polo on a
		'slump sale' basis (within the meaning of
		such term under Section 2(42C) of the
		Income-tax Act, 1961) ("Slump Sale") as a
		'going concern' as per the terms and
		conditions of the BTA and other
		documentation/ agreements executed/to be
		executed in this regard (collectively, the
		"Definitive Agreements").
2	Whether the acquisition would fall within	No
	related party transaction(s) and whether	
	the promoter/ promoter group/ group	
	companies have any interest in the entity	
	being acquired? If yes, nature of interest and details thereof and whether the same	
	is done at "arm's length	
3	Industry to which the entity being	No entity, as such, is being acquired.
	acquired belongs;	Two entity, as such, is being acquired.
	acquired belongs,	Polo, the entity whose business is being
		acquired, on a slump sale basis, is engaged
		in the business of providing diagnostics
		and pathological services.
4	Objects and effects of acquisition	The Company aims to expand its
	(including but not limited to, disclosure of	diagnostic and pathological services
	reasons for acquisition of target entity, if	business through this acquisition.
	its business is outside the main line of	
	business of the listed entity	
5	Brief details of any governmental or	No governmental or regulatory approvals
	regulatory approvals required for the	are required for this acquisition.
	acquisition	
6	Indicative time period for completion of	Subject to Long Stop of 60 Business Days
	the acquisition	from the Execution Date of the BTA and
		the fulfilment of the Conditions Precedent,
		Closing shall take place within [30 (Thirty)]
		Business Days] from the date of receipt of



Tests you can trust

		the CP Completion Certificate to the
		satisfaction of the Company.
7	Nature of consideration - whether cash	Cash Consideration.
	consideration or share swap and details of	
	the same	
8	Cost of acquisition or the price at which	Purchase consideration for acquiring
	the shares are acquired	diagnostic and pathological services
		business of Polo is Rs. 4.26 crores.
9	Percentage of shareholding / control	Not applicable as no acquisition of control/
	acquired and / or number of shares	shares/voting rights is being contemplated
	acquired	
10	Brief background about the entity	Not applicable as no acquisition of any
	acquired in terms of products/line of	entity, as such, is envisaged.
	business acquired, date of incorporation,	
	history of last 3 years turnover, country in	
	which the acquired entity has presence	
	and any other significant information	